PUBLISHER: The Business Research Company | PRODUCT CODE: 1659238
PUBLISHER: The Business Research Company | PRODUCT CODE: 1659238
Migraines, a neurological condition, are characterized by severe headaches typically felt on one side of the brain. These pulsating headaches are the primary symptom of this condition. Migraine treatment aims to alleviate these intense and often debilitating headaches by targeting the brain's pain pathways. By effectively blocking these pathways, the treatment can halt future migraine attacks and alleviate associated symptoms.
Different types of migraine treatments cater to varying migraine presentations. Episodic migraine treatment addresses instances where individuals experience headaches for 0-14 days per month. This form of treatment encompasses various acute options tailored specifically for episodic migraines. Available treatments include acute/abortive methods, preventive/prophylactic approaches, as well as non-pharmacological therapies and devices. These treatments find applications across diverse settings, including hospitals, clinics, homecare, and other end-user environments.
The migraine treatment market research report is one of a series of new reports from The Business Research Company that provides migraine treatment market statistics, including migraine treatment industry global market size, regional shares, competitors with a migraine treatment market share, detailed migraine treatment market segments, market trends and opportunities, and any further data you may need to thrive in the migraine treatment industry. This migraine treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The migraine treatment market size has grown strongly in recent years. It will grow from $3.18 billion in 2024 to $3.48 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to increased prevalence of migraines, increased healthcare expenditure, improved formulations of existing drugs, expansion of clinical research, development of novel therapies.
The migraine treatment market size is expected to see rapid growth in the next few years. It will grow to $5.32 billion in 2029 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to growing awareness and education, emergence of monoclonal antibodies, increasing focus on pediatric migraines, expansion of non-pharmacological interventions, global initiatives for migraine research. Major trends in the forecast period include advancements in therapeutic approaches, wearable devices and digital therapeutics, telemedicine and remote consultations, patient-centric care models, generic drug market growth, oral CGRP inhibitors.
The increase in prolonged screen exposure is anticipated to drive the growth of the migraine treatment market. Screen exposure refers to the duration individuals spend engaging with electronic screens, including those on smartphones, tablets, computers, and televisions. Factors contributing to prolonged screen exposure include the rise in remote work, online education, digital entertainment, and a greater reliance on technology for social interactions. Migraine treatments address symptoms that are triggered or exacerbated by extended screen time, encompassing medications, lifestyle changes, and ergonomic practices aimed at reducing strain and preventing attacks. For example, in May 2024, the House of Commons Committee, a health agency within the UK Parliament, reported that children's screen time surged by 52% in 2021, with nearly 25% of children and young people displaying smartphone usage patterns indicative of behavioral addiction. As a result, prolonged screen exposure is driving the growth of the migraine treatment market.
The escalating number of clinical trials stands as a catalyst for the migraine treatment market's expansion. These trials, involving human participants, aim to evaluate the safety and effectiveness of new medical interventions for migraines. They offer insights into personalized treatment strategies and potentially more efficient therapies. As per Xtalks in May 2023, there were 452,604 registered clinical studies on ClinicalTrials.gov, with 64,838 actively seeking participants-a significant increase from 2021's 365,000 registered trials. This surge in clinical trials actively contributes to the burgeoning migraine treatment market.
Product innovations are a prominent trend gaining traction in the migraine treatment market. Leading companies in the sector are introducing novel solutions, such as liquid formulations, to maintain their competitive edge. For example, in January 2022, BioDelivery Sciences International (BDSI), a US-based pharmaceutical firm, launched Elyxyb (celecoxib oral solution), designed for the acute treatment of migraines in adults, regardless of whether they experience aura. This liquid formulation facilitates rapid absorption in the small intestine, resulting in quicker relief compared to conventional tablets. This innovation is particularly advantageous for migraine sufferers who experience nausea or vomiting, as it eliminates the waiting time for a pill to dissolve. As the first and only FDA-approved ready-to-use oral solution for migraines, Elyxyb offers a more tolerable and efficient treatment option for managing the sudden, intense pain associated with migraines.
Major players in the migraine treatment market prioritize product approvals, such as the zavzpret (zavegepant) migraine nasal spray, to bolster market revenues. Zavzpret, a calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray, targets the acute management of adult migraines. Notably, Pfizer Inc. received FDA approval for zavzpret (zavegepant) in March 2023. This nasal spray offers immediate relief for adult migraine attacks, aiming to provide pain relief with a single spray. The FDA's endorsement marks a significant milestone for migraine sufferers seeking alternatives to oral medications for prompt pain relief.
In May 2022, Pfizer Inc., a prominent biopharmaceutical company based in the US, successfully completed the acquisition of Biohaven Pharmaceutical Holding Company Ltd. for an estimated $11.6 billion. This strategic acquisition positions Pfizer to further its commitment in providing effective treatments for individuals worldwide afflicted by migraines. Biohaven Pharmaceutical Holding Company Ltd., also based in the US, possesses a diverse product portfolio focused on addressing neuropsychiatric diseases and neurological disorders.
Major companies operating in the migraine treatment market are Pfizer Inc., Eli Lilly and Company, Amgen Inc., GlaxoSmithKline PLC, Novartis AG, Bayer AG, Allergan PLC, Abbott Laboratories, Allodynic Therapeutics LLC, AOBiome LLC, AstraZeneca PLC, Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Dr. Reddy's Laboratories Limited, Impel Pharmaceuticals Inc., AbbVie Inc., Alder BioPharmaceuticals Inc., Astellas Pharma Inc., Biohaven Pharmaceutical Holding Company Ltd., Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Endo International PLC, Impax Laboratories Inc., Johnson & Johnson Inc., Lannett Company Inc., Lupin Limited, Merck & Co. Inc., Mylan N.V.
North America was the largest region in the migraine treatment market in 2024. The regions covered in the migraine treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the migraine treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The migraine treatment market includes revenues earned by entities by providing branded and generic migraine treatment services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Migraine Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on migraine treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for migraine treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The migraine treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.